Enzon Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net income was USD 0.321 million compared to net loss of USD 0.015 million a year ago.
For the nine months, net income was USD 0.701 million compared to net loss of USD 0.519 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago.